Skip to main content
SpringerLink
Log in

Discovery of potent maternal embryonic leucine zipper kinase (MELK) inhibitors of novel chemotypes using structure-based pharmacophores

  • Original Research Article
  • Published:
Medicinal Chemistry Research Aims and scope Submit manuscript

Abstract

Maternal embryonic leucine zipper kinase (MELK) is a serine-threonine kinase. Several studies have revealed its role as a regulator in the tumorigenesis of various cancers. Consequently, MELK has been considered as an attractive therapeutic target for cancer management. Herein, we report pharmacophore models extracted from crystallographic complexes of potent ligands bound to MELK protein. The resulting models were evaluated by Receiver Operating Characteristic (ROC) analysis, and the best models were employed as search queries to screen the national cancer institute for potent inhibitors. The anti-MELK bioactivities of acquired hits were evaluated in vitro. Moreover, best anti-MELK hits were further evaluated against lung and cervical cancer cells (A549 and HeLa, respectively) using cell viability MTT assay. The enzymatic assay identified six potent hits with IC50 values ranging from nanomolar to low micromolar values. The most active hit showed anti-MELK IC50 of 134.6 nM. Likewise, these hits significantly inhibited the growth of tested cancer cell lines. Interestingly, four of the identified inhibitors have chemical scaffolds that are notably different from those of reported MELK inhibitors. This study highlights the use of X-ray crystallographic structures to boost the drug discovery process.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

Data availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author upon reasonable request.

References

  1. Tang Q, Li W, Zheng X, Ren L, Liu J, Li S, et al. MELK is an oncogenic kinase essential for metastasis, mitotic progression, and programmed death in lung carcinoma. Signal Transduct Target Ther. 2020;5:279.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Das A, Prajapati A, Karna A, Sharma HK, Uppal S, Lather V, et al. Structure-based virtual screening of chemical libraries as potential MELK inhibitors and their therapeutic evaluation against breast cancer. Chem Biol Interact. 2023;376:110443.

    Article  CAS  PubMed  Google Scholar 

  3. Ren L, Guo J-S, Li Y-H, Dong G, Li X-Y. Structural classification of MELK inhibitors and prospects for the treatment of tumor resistance: a review. Biomed Pharmacother. 2022;156:113965.

    Article  CAS  PubMed  Google Scholar 

  4. Ganguly R, Mohyeldin A, Thiel J, Kornblum HI, Beullens M, Nakano I. MELK—a conserved kinase: functions, signaling, cancer, and controversy. Clin Transl Med. 2015;4:1–8.

    Article  Google Scholar 

  5. Jiang P, Zhang D. Maternal embryonic leucine zipper kinase (MELK): a novel regulator in cell cycle control, embryonic development, and cancer. Int J Mol Sci. 2013;14:21551–60.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Yang H, Zhou H, Wang G, Tian L, Li H, Zhang Y, et al. MELK is a prognostic biomarker and correlated with immune infiltration in glioma. Front Neurol. 2022;13:977180–95.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Sun H, Ma H, Zhang H, Ji M. Up-regulation of MELK by E2F1 promotes the proliferation in cervical cancer cells. Int J Biol Sci. 2021;17:3875.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Li G, Yang M, Zuo L, Wang MX. MELK as a potential target to control cell proliferation in triple‑negative breast cancer MDA‑MB‑231 cells. Oncol Lett. 2018;15:9934–40.

    PubMed  PubMed Central  Google Scholar 

  9. Talib WH, Alsayed AR, Barakat M, Abu-Taha MI, Mahmod AI. Targeting drug chemo-resistance in cancer using natural products. Biomedicines 2021;9:1353.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Zhang Y, Zhou X, Li Y, Xu Y, Lu K, Li P, et al. Inhibition of maternal embryonic leucine zipper kinase with OTSSP167 displays potent anti-leukemic effects in chronic lymphocytic leukemia. Oncogene. 2018;37:5520–33.

    Article  CAS  PubMed  Google Scholar 

  11. Klaeger S, Heinzlmeir S, Wilhelm M, Polzer H, Vick B, Koenig P-A, et al. The target landscape of clinical kinase drugs. Science. 2017;358:eaan4368.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Ji W, Arnst C, Tipton AR, Bekier ME, Taylor WR, Yen TJ, et al. OTSSP167 abrogates mitotic checkpoint through inhibiting multiple mitotic kinases. PLoS One. 2016;15:e0153518.

    Article  Google Scholar 

  13. Chung S, Suzuki H, Miyamoto T, Takamatsu N, Tatsuguchi A, Ueda K, et al. Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer. Oncotarget. 2012;3:1629.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Kapale SS, Mali SN, Chaudhari HK. Molecular modelling studies for 4-oxo-1, 4-dihydroquinoline-3-carboxamide derivatives as anticancer agents. Med Drug Discov. 2019;2:100008.

    Article  Google Scholar 

  15. Siju E, Rajalakshmi G, Paulose AP, Dhanya F, Hariraj N, Rahul K CADD: pharmacological approaches in drug design and drug discovery. World J Pharm Pharm Sci. 2017;892–908.

  16. Gao Q, Yang L, Zhu Y. Pharmacophore-based drug design approach as a practical process in drug discovery. Curr Comput Aided Drug Des. 2010;6:37–49.

    Article  CAS  PubMed  Google Scholar 

  17. Abuhammad A, Taha M. Innovative computer-aided methods for the discovery of new kinase ligands. Future Med Chem. 2016;8:509–26.

    Article  CAS  PubMed  Google Scholar 

  18. Aparoy P, Kumar Reddy K, Reddanna P. Structure and ligand-based drug design strategies in the development of novel 5-LOX inhibitors. Curr Med Chem. 2012;19:3763–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Al-Sha’er MA, Mansi I, Khanfar M, Abudayyh A. Discovery of new heat shock protein 90 inhibitors using virtual co-crystallized pharmacophore generation. J Enzym Inhib Med Chem. 2016;31:64–77.

    Article  Google Scholar 

  20. Böhm H-J, Flohr A, Stahl M. Scaffold hopping. Drug Discov Today Technol. 2004;1:217–24.

    Article  PubMed  Google Scholar 

  21. Hu Y, Stumpfe D, Bajorath J, Jr.Recent advances in scaffold hopping.J Med Chem. 2017;60:1238–46.

    Article  CAS  PubMed  Google Scholar 

  22. Yang S-Y. Pharmacophore modeling and applications in drug discovery: challenges and recent advances. Drug Discov Today Technol. 2010;15:444–50.

    Article  CAS  Google Scholar 

  23. Hessler G, Baringhaus K-H. The scaffold hopping potential of pharmacophores. Drug Discov Today Technol. 2010;7:e263–e269.

    Article  CAS  Google Scholar 

  24. Zhou S, Li GB, Luo L, Zhong L, Chen K, Li H, et al. Structure-based discovery of new maternal embryonic leucine zipper kinase inhibitors. Org Biomol Chem. 2018;16:1489–95.

    Article  CAS  PubMed  Google Scholar 

  25. Carvalho AL, Trincão J, Romão MJ. X-ray crystallography in drug discovery. Methods Mol Biol. 2009;572:31–56.

    Article  PubMed  Google Scholar 

  26. Zheng H, Hou J, Zimmerman MD, Wlodawer A, Minor W. The future of crystallography in drug discovery. Expert Opin Drug Discov. 2014;9:125–37.

    Article  CAS  PubMed  Google Scholar 

  27. Triballeau N, Acher F, Brabet I, Pin J-P, Bertrand H-O. Virtual screening workflow development guided by the “receiver operating characteristic” curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4. J Med Chem. 2005;48:2534–47.

    Article  CAS  PubMed  Google Scholar 

  28. Daoud S, Taha M. Ligand-based modeling of CXC chemokine receptor 4 and identification of inhibitors of novel chemotypes as potential leads towards new anti-COVID-19 treatments. Med Chem. 2022;18:871–83.

    Article  CAS  PubMed  Google Scholar 

  29. Irwin JJ, Shoichet BK. ZINC− a free database of commercially available compounds for virtual screening. J Chem Inf Model. 2005;45:177–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Kirchmair J, Distinto S, Markt P, Schuster D, Spitzer GM, Liedl KR, et al. How to optimize shape-based virtual screening: choosing the right query and including chemical information. J Chem Inf Model 2009;49:678–92.

    Article  CAS  PubMed  Google Scholar 

  31. Kirchmair J, Markt P, Distinto S, Wolber G, Langer T. Evaluation of the performance of 3D virtual screening protocols: RMSD comparisons, enrichment assessments, and decoy selection—what can we learn from earlier mistakes? J Comput Aided Mol Des. 2008;22:213–28.

    Article  CAS  PubMed  Google Scholar 

  32. Al-Tawil MF, Daoud S, Ma’mon MH, Taha MO. Discovery of new Cdc2-like kinase 4 (CLK4) inhibitors via pharmacophore exploration combined with flexible docking-based ligand/receptor contact fingerprints and machine learning. RSC Adv. 2022;12:10686–700.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Shoichet BK. Interpreting steep dose-response curves in early inhibitor discovery. J Med Chem. 2006;49:7274–7.

    Article  CAS  PubMed  Google Scholar 

  34. Mousa LA, Hatmal MMM, Taha M. Exploiting activity cliffs for building pharmacophore models and comparison with other pharmacophore generation methods: sphingosine kinase 1 as case study. J Comput Aided Mol Des. 2022;36:39–62.

    Article  CAS  PubMed  Google Scholar 

  35. Sjöstedt E, Zhong W, Fagerberg L, Karlsson M, Mitsios N, Adori C, et al. An atlas of the protein-coding genes in the human, pig, and mouse brain. Science. 2020;367:eaay5947.

    Article  PubMed  Google Scholar 

  36. Kelder J, Grootenhuis PD, Bayada DM, Delbressine LP, Ploemen JP. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm Res. 1999;16:1514–9.

    Article  CAS  PubMed  Google Scholar 

  37. Berman H, Henrick K, Nakamura H. Announcing the worldwide protein data bank. Nat Struct Mol Biol. 2003;10:980.

    Article  CAS  Google Scholar 

  38. Wolber G, Langer T. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J Chem Inf Model. 2005;45:160–9.

    Article  CAS  PubMed  Google Scholar 

  39. Mansi IA, Al-Sha’er MA, Mhaidat NM, Taha MO, Shahin R. Investigation of binding characteristics of Phosphoinositide-dependent kinase-1 (PDK1) co-crystallized ligands through virtual pharmacophore modeling leading to novel anti-PDK1 hits. Med Chem. 2020;16:860–80.

    Article  CAS  PubMed  Google Scholar 

  40. Al-Sha’er MA, Mansi I, Almazari I, Hakooz N. Evaluation of novel Akt1 inhibitors as anticancer agents using virtual co-crystallized pharmacophore generation. J Mol Graph Model. 2015;62:213–25.

    Article  PubMed  Google Scholar 

  41. Lipinski CA. Lead-and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol. 2004;1:337–41.

    Article  CAS  PubMed  Google Scholar 

  42. Antony J, Tkachenko V, Lipinski C, Ekins S. Free online resources enabling crowd-sourced drug discovery. Drug Discov Today Technol. 2009;10:33.

    Google Scholar 

  43. Ma H, Deacon S, Horiuchi K. The challenge of selecting protein kinase assays for lead discovery optimization. Expert Opin Drug Discov. 2008;3:607–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Bardaweel S, Aljanabi R, Sabbah D, Sweidan K. Design, synthesis, and biological evaluation of novel MAO-A inhibitors targeting lung cancer. Molecules. 2022;27:2887.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Bardaweel SK, Tawaha KA, Hudaib MM. Antioxidant, antimicrobial and antiproliferative activities of Anthemis palestina essential oil. BMC Complement Altern Med. 2014;14:1–8.

    Article  Google Scholar 

  46. Rahal BA, Bardaweel SK. Implications and efficacy of aromatase inhibitors in combination and monotherapy for the treatment of lung cancer. Anticancer Agents Med Chem. 2022;22:3114–24.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank the Deanships of Scientific Research at the Applied Sciences Private University (Amman) and University of Jordan for sponsoring this project.

Funding

This work was supported by the Deanships of Scientific Research at the Applied Sciences Private University (Amman) and University of Jordan.

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Chemistry and Pharmacognosy, Faculty of Pharmacy, Applied Science Private University, Amman, Jordan

    Safa Daoud

  2. Department of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan

    Shada J. Alabed

  3. Department of Pharmaceutical Sciences, Faculty of Pharmacy, University of Jordan, Amman, Jordan

    Sanaa K. Bardaweel & Mutasem O. Taha

Authors
  1. Safa Daoud
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shada J. Alabed
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sanaa K. Bardaweel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mutasem O. Taha
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SD: Investigation, Formal analysis, Writing, Review & Editing. SJA: Formal analysis, Review & Editing. SB: Formal analysis, Review & Editing. MOT Conceptualization, Methodology, Supervision, Investigation, Resources, Writing, Review & Editing.

Corresponding author

Correspondence to Mutasem O. Taha.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Daoud, S., Alabed, S.J., Bardaweel, S.K. et al. Discovery of potent maternal embryonic leucine zipper kinase (MELK) inhibitors of novel chemotypes using structure-based pharmacophores. Med Chem Res 32, 2574–2586 (2023). https://doi.org/10.1007/s00044-023-03160-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00044-023-03160-5

Keywords

Search

Navigation